RIGEL PHARMACEUTICALS INC (RIGL) Fundamental Analysis & Valuation

NASDAQ:RIGL • US7665597024

Current stock price

25.95 USD
-0.65 (-2.44%)
At close:
26.1331 USD
+0.18 (+0.71%)
After Hours:

This RIGL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. RIGL Profitability Analysis

1.1 Basic Checks

  • In the past year RIGL was profitable.
  • In the past year RIGL had a positive cash flow from operations.
  • In the past 5 years RIGL reported 4 times negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: RIGL reported negative operating cash flow in multiple years.
RIGL Yearly Net Income VS EBIT VS OCF VS FCFRIGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 46.72%, RIGL belongs to the top of the industry, outperforming 99.23% of the companies in the same industry.
  • RIGL's Return On Equity of 96.34% is amongst the best of the industry. RIGL outperforms 99.42% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 63.44%, RIGL belongs to the top of the industry, outperforming 99.61% of the companies in the same industry.
Industry RankSector Rank
ROA 46.72%
ROE 96.34%
ROIC 63.44%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RIGL Yearly ROA, ROE, ROICRIGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

  • The Profit Margin of RIGL (40.17%) is better than 97.69% of its industry peers.
  • RIGL has a Operating Margin of 42.17%. This is amongst the best in the industry. RIGL outperforms 99.04% of its industry peers.
  • The Gross Margin of RIGL (93.10%) is better than 93.45% of its industry peers.
  • RIGL's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 42.17%
PM (TTM) 40.17%
GM 93.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
RIGL Yearly Profit, Operating, Gross MarginsRIGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

6

2. RIGL Health Analysis

2.1 Basic Checks

  • RIGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • RIGL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RIGL Yearly Shares OutstandingRIGL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
RIGL Yearly Total Debt VS Total AssetsRIGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • RIGL has an Altman-Z score of -1.76. This is a bad value and indicates that RIGL is not financially healthy and even has some risk of bankruptcy.
  • RIGL's Altman-Z score of -1.76 is in line compared to the rest of the industry. RIGL outperforms 50.48% of its industry peers.
  • RIGL has a debt to FCF ratio of 0.88. This is a very positive value and a sign of high solvency as it would only need 0.88 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 0.88, RIGL belongs to the top of the industry, outperforming 94.80% of the companies in the same industry.
  • A Debt/Equity ratio of 0.25 indicates that RIGL is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.25, RIGL is not doing good in the industry: 65.70% of the companies in the same industry are doing better.
  • Even though the debt/equity ratio score it not favorable for RIGL, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 0.88
Altman-Z -1.76
ROIC/WACC6.87
WACC9.24%
RIGL Yearly LT Debt VS Equity VS FCFRIGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 2.28 indicates that RIGL has no problem at all paying its short term obligations.
  • RIGL has a worse Current ratio (2.28) than 73.60% of its industry peers.
  • A Quick Ratio of 2.14 indicates that RIGL has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.14, RIGL is doing worse than 73.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.28
Quick Ratio 2.14
RIGL Yearly Current Assets VS Current LiabilitesRIGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2

3. RIGL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 593.62% over the past year.
EPS 1Y (TTM)593.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%21.19%

3.2 Future

  • Based on estimates for the next years, RIGL will show a decrease in Earnings Per Share. The EPS will decrease by -2.44% on average per year.
  • The Revenue is expected to grow by 6.25% on average over the next years.
EPS Next Y-36.48%
EPS Next 2Y-13.06%
EPS Next 3Y-8.59%
EPS Next 5Y-2.44%
Revenue Next Year-3.44%
Revenue Next 2Y4.1%
Revenue Next 3Y9.65%
Revenue Next 5Y6.25%

3.3 Evolution

RIGL Yearly Revenue VS EstimatesRIGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
RIGL Yearly EPS VS EstimatesRIGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5

8

4. RIGL Valuation Analysis

4.1 Price/Earnings Ratio

  • RIGL is valuated cheaply with a Price/Earnings ratio of 3.98.
  • Compared to the rest of the industry, the Price/Earnings ratio of RIGL indicates a rather cheap valuation: RIGL is cheaper than 99.42% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of RIGL to the average of the S&P500 Index (25.70), we can say RIGL is valued rather cheaply.
  • RIGL is valuated cheaply with a Price/Forward Earnings ratio of 6.27.
  • 98.46% of the companies in the same industry are more expensive than RIGL, based on the Price/Forward Earnings ratio.
  • RIGL's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.84.
Industry RankSector Rank
PE 3.98
Fwd PE 6.27
RIGL Price Earnings VS Forward Price EarningsRIGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, RIGL is valued cheaply inside the industry as 99.23% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, RIGL is valued cheaper than 98.84% of the companies in the same industry.
Industry RankSector Rank
P/FCF 6.91
EV/EBITDA 2.61
RIGL Per share dataRIGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The decent profitability rating of RIGL may justify a higher PE ratio.
  • RIGL's earnings are expected to decrease with -8.59% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.06%
EPS Next 3Y-8.59%

0

5. RIGL Dividend Analysis

5.1 Amount

  • RIGL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

RIGL Fundamentals: All Metrics, Ratios and Statistics

RIGEL PHARMACEUTICALS INC

NASDAQ:RIGL (3/13/2026, 8:00:02 PM)

After market: 26.1331 +0.18 (+0.71%)

25.95

-0.65 (-2.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03
Earnings (Next)05-04
Inst Owners91.09%
Inst Owner Change6.53%
Ins Owners3.09%
Ins Owner Change6.76%
Market Cap470.99M
Revenue(TTM)N/A
Net Income(TTM)113.30M
Analysts80
Price Target47.94 (84.74%)
Short Float %21.57%
Short Ratio9.16
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.05%
Min EPS beat(2)24.64%
Max EPS beat(2)67.46%
EPS beat(4)4
Avg EPS beat(4)188.12%
Min EPS beat(4)24.64%
Max EPS beat(4)592.43%
EPS beat(8)7
Avg EPS beat(8)242.36%
EPS beat(12)11
Avg EPS beat(12)181.29%
EPS beat(16)14
Avg EPS beat(16)138.58%
Revenue beat(2)2
Avg Revenue beat(2)11.07%
Min Revenue beat(2)10.05%
Max Revenue beat(2)12.08%
Revenue beat(4)4
Avg Revenue beat(4)12.62%
Min Revenue beat(4)9.15%
Max Revenue beat(4)19.17%
Revenue beat(8)7
Avg Revenue beat(8)10.41%
Revenue beat(12)11
Avg Revenue beat(12)14.43%
Revenue beat(16)12
Avg Revenue beat(16)11.18%
PT rev (1m)0%
PT rev (3m)3.68%
EPS NQ rev (1m)7.09%
EPS NQ rev (3m)17.09%
EPS NY rev (1m)0.23%
EPS NY rev (3m)1.14%
Revenue NQ rev (1m)1.14%
Revenue NQ rev (3m)3.4%
Revenue NY rev (1m)0.27%
Revenue NY rev (3m)0.78%
Valuation
Industry RankSector Rank
PE 3.98
Fwd PE 6.27
P/S 1.67
P/FCF 6.91
P/OCF 6.91
P/B 4
P/tB 5.1
EV/EBITDA 2.61
EPS(TTM)6.52
EY25.13%
EPS(NY)4.14
Fwd EY15.96%
FCF(TTM)3.75
FCFY14.47%
OCF(TTM)3.76
OCFY14.48%
SpS15.54
BVpS6.48
TBVpS5.08
PEG (NY)N/A
PEG (5Y)N/A
Graham Number30.83
Profitability
Industry RankSector Rank
ROA 46.72%
ROE 96.34%
ROCE 80.3%
ROIC 63.44%
ROICexc 854.98%
ROICexgc N/A
OM 42.17%
PM (TTM) 40.17%
GM 93.1%
FCFM 24.16%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score7
Asset Turnover1.16
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 0.88
Debt/EBITDA 0.25
Cap/Depr 1.57%
Cap/Sales 0.01%
Interest Coverage 17.61
Cash Conversion 56.17%
Profit Quality 60.14%
Current Ratio 2.28
Quick Ratio 2.14
Altman-Z -1.76
F-Score7
WACC9.24%
ROIC/WACC6.87
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)593.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.75%
EPS Next Y-36.48%
EPS Next 2Y-13.06%
EPS Next 3Y-8.59%
EPS Next 5Y-2.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%21.19%
Revenue Next Year-3.44%
Revenue Next 2Y4.1%
Revenue Next 3Y9.65%
Revenue Next 5Y6.25%
EBIT growth 1Y1151.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year546.96%
EBIT Next 3Y91.91%
EBIT Next 5Y95.89%
FCF growth 1Y286.79%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y418.44%
OCF growth 3Y74.92%
OCF growth 5YN/A

RIGEL PHARMACEUTICALS INC / RIGL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?

ChartMill assigns a fundamental rating of 5 / 10 to RIGL.


What is the valuation status for RIGL stock?

ChartMill assigns a valuation rating of 8 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.


Can you provide the profitability details for RIGEL PHARMACEUTICALS INC?

RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.


How financially healthy is RIGEL PHARMACEUTICALS INC?

The financial health rating of RIGEL PHARMACEUTICALS INC (RIGL) is 6 / 10.